Navigation Links
Pharmasset Reports Fiscal Year End 2011 Financial Results
Date:11/14/2011

0;Screening and enrollment for this open-label study have progressed quickly, and interim results from the first half of the subjects enrolled are anticipated in the second calendar quarter of 2012.

MericitabineRoche is currently conducting a number of phase 2 studies with mericitabine, including the INFORM-SVR study in combination with ritonavir-boosted danoprevir with and without ribavirin for 12 or 24 weeks in patients with HCV GT1. Roche recently announced an additional arm added to INFORM-SVR to assess a 24 week regimen of mericitabine, boosted danoprevir and ribavirin in HCV genotype 1 patients contraindicated for or intolerant of interferon. In June 2011, Roche initiated a second trial, MATTERHORN, to evaluate ritonavir-boosted danoprevir and ribavirin in combination with mericitabine and/or pegylated interferon. The study is expected to enroll approximately 420 subjects with HCV GT1 who failed previous therapy. Roche has stated that it intends to file mericitabine for marketing approval in 2014.

Financial ResultsFor the fiscal year ended September 30, 2011 Pharmasset reported revenues of $0.9 million, compared with revenues of $1.0 million for fiscal year 2010. Revenues during each fiscal year primarily consist of amortization of up-front and subsequent collaborative and license payments received from Roche previously recorded as deferred revenue.  

Total costs and expenses for the fiscal year ended September 30, 2011 were $92.5 million compared to $64.7 million for the same period in 2010. The increase in operating expenses was primarily the result of increased clinical development costs associated with the initiation and ongoing conduct of the Phase 2 studies ELECTRON and ATOMIC, as well as the advancement of PSI-938 in NUCLEAR and the large Phase 2b study, QUANTUM.

Pharmasset reported a net loss of $91.2 million, or $1.25 per share for the fiscal year ended September 30, 2011, as compared to a net loss of $66
'/>"/>

SOURCE Pharmasset, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Pharmasset to Present at the Canaccord Adams Global Growth Conference on Tuesday, August 12th
2. Pharmasset to Present at the Upcoming Citibank and Morgan Stanley Investor Conferences
3. Pharmasset Reports Preliminary Results of a 4-week Proof-of-Concept Combination Study of R7128 for the Treatment of Chronic Hepatitis C in Genotype 2 or 3 Non-Responders
4. Pharmasset to Present at the JMP Securities Healthcare Focus Conference on Monday, October 6th
5. Pharmasset to Present at the Natixis Bleichroeder Hidden Gems Conference on Monday, October 13th
6. Pharmasset to Present at Two Upcoming Investor Conferences
7. Pharmasset and Roche Obtain FDA Consent to Start a Phase 2b Study With R7128 in Treatment Naive HCV Patients
8. Pharmasset Announces $45.5 Million Registered Direct Offering of Common Stock
9. Pharmasset Reports Fiscal First Quarter 2009 Financial Results
10. InterMune and Pharmasset to Discuss INFORM-1 Results From EASL Conference, April 25
11. Pharmasset Reports Fiscal Second Quarter 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... May 17, 2013 /PRNewswire-iReach/ -- Aridis is pleased ... with Switzerland -based Kenta Biotech ... monoclonal antibody (mAb) products, and technologies. This asset ... for treatment of infections by common pathogens including ... , Pseudomonas aeruginosa , Acinetobacter baumannii ...
(Date:5/17/2013)... May 17, 2013 Men’s skin is biologically ... La-roche Posay ) and has been known to react more ... men may be far from puberty, other acne causing factors ... causing breakouts, and threatening skin with unsightly acne scars. Adult ... Men’s Health on how to reduce and prevent ...
(Date:5/17/2013)... RURO Inc. is pleased to ... versatile refinement to the smart management solution. , ... advanced methodical management for transgenic animal colonies, genotyping ... network-based platform provides user access with a plethora ... to emphasize streamlined tasks, such as animal relocation ...
(Date:5/17/2013)... 2013 IAC Industries wants to share with ... laboratory needing to set up and furnish a research lab ... facility within a year’s time. How does a company make ... is temporary? What is efficient and cost-effective? , The ... IAC Industries. The planners at DisperSol determined that the concept ...
Breaking Biology Technology:Aridis Pharmaceuticals Announces Acquisition of Monoclonal Antibody Products and Technologies From Kenta Biotech 2Aridis Pharmaceuticals Announces Acquisition of Monoclonal Antibody Products and Technologies From Kenta Biotech 3Adult Acne Treatment, Probiotic Action Shares New Insight on Why Men’s Skin Scars from Acne and How to Prevent It 2RURO Introduces ezColony 4.1 – The Versatile Transgenic Animal Colony Management Software 2New Downloadable Success Story: “How To Outfit a Dynamic Lab in Flux” 2
... ST. PETERS, Mo., Sept. 11 MEMC Electronic,Materials, ... update related to Hurricane,Ike., The company reported ... Pasadena, Texas facility in preparation for Hurricane Ike. ... shutting down operations in,preparation for the heavy weather ...
... Neurobiological,Technologies, Inc. (NTI(R)) (Nasdaq: NTII ), today announced ... financial results on September,16, 2008., The Company will ... for the fiscal year-end call are as follows:, ... Time: 10:30 a.m. ET, 9:30 a.m. CT, 7:30 a.m. ...
... of food supply, as well as increasing concerns about environmental ... spiraling growth given the recent success of commercialized products and ... , ... San Jose, California (PRWEB) September ...
Cached Biology Technology:MEMC Provides Update on Hurricane Ike 2Neurobiological Technologies Announces Dates for 2008 Fiscal Year End Financial Results Conference Call and Presentation at MCF Investor Summit 2Long-Term Investments Remain Critical to Biotechnology Industry Growth, According to a New Report by Global Industry Analysts 2Long-Term Investments Remain Critical to Biotechnology Industry Growth, According to a New Report by Global Industry Analysts 3Long-Term Investments Remain Critical to Biotechnology Industry Growth, According to a New Report by Global Industry Analysts 4
(Date:5/15/2013)... benefit in moderating gout risk, new research reveals that ... uric acid (urate) levels to a clinically significant degree ... or in combination with allopurinol, appears to have a ... patients according to the results published in the American ... . , Gout is an inflammatory arthritis that ...
(Date:5/15/2013)... clinical trial to date to examine the efficacy of ... other than breast and ovarian cancer, the oral drug ... and prostate cancers. Results of the study, led by ... University of Pennsylvania and Sheba Medical Center in Tel ... of Clinical Oncology,s annual meeting in Chicago in early ...
(Date:5/15/2013)... from the middle Devonian era some 380 million ... of the capacity of ecosystems to remain stable in ... today (May 15) in the online journal PLOS ... the head counts of specimens paleontologists test the ... factors such as predation and organism body size from ...
Breaking Biology News(10 mins):Vitamin C does not lower uric acid levels in gout patients 2PARP inhibitor shows activity in pancreatic, prostate cancers among patients carrying BRCA mutations 2Clam fossils divulge secrets of ecologic stability 2
... Tropical rain forests are treasure houses of biodiversity, but ... monitor their plant species over large areas. As a ... clearing, invasive plants, and other threats are affecting these ... is in the works, however. Gregory Asner of the ...
... pond,s edge eyeing a cricket on a blade of grass. ... insect with its tongue. This deceptively simple, remarkably fast feeding ... This fresh perspective could lead to designing more efficient electric ... like Parkinson,s. Science has long held that muscles behave ...
... A study from researchers at Children,s Hospital ... infection control intervention in elementary schools disinfecting ... helped reduce illness-related student absenteeism. ... millions of lost school days each year.(1) ...
Cached Biology News:Revolution in rain forest monitoring with MacArthur grant 2Toad research could leapfrog to new muscle model 2Study findings show infection control intervention helps keep kids in school 2
The FailSafe™ PROBES Real-Time PCR System enables rapid, precise optimization of PCR experiments in which the product is detected using fluorescent target-specific labeled probes....
Anti-hamster Ig HRP detection kit...
...
...
Biology Products: